Related Experiment Video
Updated: Mar 5, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.7K
Quality indicators for early stage Hodgkin's lymphoma
Daniel E Roos1,2, Hui C Tee1
1Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Journal of Medical Imaging and Radiation Oncology
|March 28, 2017
Summary
Developing quality indicators (QIs) for early-stage Hodgkin
Area of Science:
- Oncology
- Clinical Quality Improvement
- Evidence-Based Medicine
Background:
- Early-stage Hodgkin's lymphoma (ESHL) treatment requires adherence to established guidelines.
- Assessing treatment quality is crucial for patient outcomes.
- Existing quality indicators (QIs) for ESHL may need refinement for practical application.
Purpose of the Study:
- To develop and retrospectively test practical quality indicators (QIs) for early-stage Hodgkin's lymphoma (ESHL) treatment.
- To evaluate the applicability of these QIs in a real-world clinical setting.
Main Methods:
- Selected nine QIs from eviQ guidelines for ESHL (favourable and unfavourable).
- Retrospectively analyzed data from ESHL patients treated at a large teaching hospital (July 2009-July 2014).
- Calculated QI scores based on adherence to chemotherapy and radiotherapy recommendations.
Main Results:
- Raw QI scores ranged from 74-100%, with corrected scores from 83-100%.
- Improvement potential identified in chemotherapy cycles (87% corrected) and radiotherapy dose (83% corrected).
- Compliance was nearly perfect after the eviQ guidelines were published.
Conclusions:
- The developed QIs for ESHL are practical and applicable in a single-center review.
- Overall compliance with ESHL treatment guidelines was high, particularly after guideline publication.
- Reporting raw and corrected QI scores is recommended for ongoing quality assessment.
